MK-677 (Ibutamoren) — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

MK-677 (Ibutamoren)

Also known as: Ibutamoren, Ibutamoren mesylate, MK-0677, MK0677, Ibutamoren Mesylate

Growth Hormone Secretagogue (GHS) / Ghrelin Receptor Agonist (non-peptide, orally active spiroindoline derivative)

Research chemicalLast updated: October 31, 2026Based on 26 peer-reviewed studies

What it is

MK-677 (ibutamoren) is an oral compound people take to raise growth hormone and IGF-1 levels for muscle preservation, fat loss, better sleep, and recovery from aging or illness. It works by mimicking ghrelin to trigger GH release from the pituitary. Not FDA-approved; banned by WADA; studied in clinical trials for sarcopenia and bone health.

The scientific side

MK-677 is an orally active, non-peptide spiroindoline derivative that acts as a potent agonist at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor (PMID 36354265; PMID 28400207). It mimics the endogenous peptide ghrelin, binding to and activating GHS-R1a expressed predominantly in the brain, pituitary gland, and pancreas, as well as in peripheral tissues including the heart, adrenals, and gonads (PMID 15814848; PMID 11061542). Receptor activation stimulates pulsatile release of endogenous growth hormone (GH) through multiple mechanisms: increasing GHRH release, amplifying GHRH signaling in pituitary somatotrophs, reducing somatostatin release, and antagonizing somatostatin receptor signaling. GH release in turn stimulates hepatic and peripheral production of insulin-like growth factor-1 (IGF-1). Pharmacological studies demonstrate that MK-677 functions as an orthosteric agonist at GHS-R1a, competing directly with ghrelin for the same binding site at the interface of transmembrane domains III and VI, and displaying higher intrinsic efficacy than ghrelin itself in some assay systems (PMID 19625579; PMID 18923064; PMID 15905359). Unlike exogenous GH administration, GHS-mediated GH release remains subject to normal negative feedback, theoretically reducing the risk of supra-therapeutic GH levels.

Class: Growth Hormone Secretagogue (GHS) / Ghrelin Receptor Agonist (non-peptide, orally active spiroindoline derivative)

Administration & storage

Administration
Oral administration (capsule/tablet) — the only route reported in the reviewed human clinical abstracts (PMID: 18981485; PMID: 9467534; PMID: 21067829; PMID: 15066065; PMID: 11238495; PMID: 10404019)
Storage
No storage conditions for MK-677 are described in the reviewed abstracts.
Cautions
A clinical trial of MK-677 25 mg/day in elderly hip-fracture patients was terminated early due to a safety signal of congestive heart failure in a limited number of patients; MK-677 was described as having an unfavorable safety profile in this population.,MK-677 consistently increased fasting blood glucose and decreased insulin sensitivity in human RCTs; monitoring of glucose homeostasis is warranted (PMID: 18981485; PMID: 9467542).,A case report documents hepatotoxicity (transaminitis) in a man in his early 30s who consumed MK-677 for 2 months; liver function tests normalized after stopping the supplement.,At a dose of 3 mg/kg in transgenic mice (5xFAD), MK0677 significantly increased mortality; the clinical relevance of this finding is unknown.,MK-677 is found unlabeled in commercially available dietary supplements; products may contain undisclosed additional compounds including SARMs and undisclosed steroid hormones, representing a significant purity and contamination risk (PMID: 33934684; PMID: 39145153).,Use of sterile technique applies to any injectable compound; however, all reviewed clinical studies used oral administration only — injection of non-pharmaceutical-grade material carries unknown risks.

Legal & regulatory status

US FDA

Not approved as a drug by the FDA for any indication per the reviewed literature. Reviewed literature notes strict FDA criteria for GH use and describes MK-677 as an investigational compound. Detected unlabeled in…

WADA

Listed on the World Anti-Doping Agency prohibited list. Described as a banned performance-enhancing drug.

Health Canada

Not stated in reviewed literature — requires manual verification